“…For decades, the use of beta-blockers has been considered a cornerstone of medical therapy after ACS, having a class I or a class IIa indication for patients after STEMI and non-STEMI, respectively. 19,20 However, in the era of reperfusion therapy, several studies have questioned this indication, especially in patients without left ventricular dysfunction. 21,22 In the November issue of Rev Port Cardiol, Timoteo et al.…”